Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYCETIN versus COR OTICIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYCETIN versus COR OTICIN.
CHLOROMYCETIN vs COR-OTICIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
50-100 mg/kg/day IV divided every 6 hours; maximum 4 g/day. Topical: apply to affected area 2-4 times daily.
1-2 drops in each affected ear twice daily for 7 days.
None Documented
None Documented
1.5-4 hours in adults; prolonged to 3-7 hours in neonates and 4-12 hours in hepatic impairment; clinical context: dose adjustment required in liver disease.
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Renal: 5-10% unchanged; hepatic glucuronidation (90%) followed by renal elimination of metabolites; small biliary excretion (<5%) and fecal elimination.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Category C
Category C
Antibiotic
Topical Corticosteroid + Antibiotic